This is a routine insider onboarding filing with no trading or ownership implications. No further action warranted.
OCUL drugs
OCUL drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 11 $6.66entry
- T+1 · 5d ago −5.71%α −5.35% · $6.28
- T+3 · todayOpen
- T+5 · tomorrow Pending
- T+20 · in 23d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Riad Sherif filed an initial statement of beneficial ownership (Form 3) with Ocular Therapeutix, reporting no securities owned. The filing is a routine administrative requirement for a new insider and includes a power of attorney authorizing others to file SEC reports on his behalf.
Key Facts
- Riad Sherif filed a Form 3 initial statement of beneficial ownership on November 10, 2026, with a period of report of November 6, 2026.
- The filing reports 0 shares, 0 derivative securities, and 0 other securities owned.
- A power of attorney (Exhibit 24) was included, appointing Donald Notman, Todd Anderman, Jason Robins, and Kathleen Theriault as attorneys-in-fact for SEC filing purposes.
- The filing is administrative and contains no financial data, transactions, or material corporate events.
Financial Impact
No financial impact; the filing reports zero beneficial ownership.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001104659-26-125169 |
| Document: 0001104659-26-125169-index-headers.html | 0001104659-26-125169 |
| Document: 0001104659-26-125169-index.html | 0001104659-26-125169 |
| Document: 0001104659-26-125169.txt | 0001104659-26-125169 |
Track record
20 reports on OCUL
4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +24.88% at T+20 after the Aug 3, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 10, 20266d ago 3 Neutral 2/10 Viewing Entry $6.66 Now $6.01 −9.76% settles Nov 18
- Nov 9, 20267d ago 8-K Neutral 2/10 Entry $6.85 to $6.01 Now $6.01 −12.26% ▼ −12.26% −10.57% vs SPY
- Nov 9, 20267d ago Press Release Bearish 5/10 Entry $6.85 to $6.01 Now $6.01 +12.26% ▲ +12.26% +10.57% vs SPY
- Nov 5, 202611d ago 144 Neutral 3/10 Entry $6.60 to $6.21 Now $6.01 −8.87% ▼ −5.84% −8.43% vs SPY
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $6.29 to $6.47 Now $6.01 −4.45% ▲ +2.86% +3.01% vs SPY
- Oct 8, 20265w ago 144 Neutral 2/10 Entry $7.54 to $6.87 Now $6.01 −20.29% ▼ −8.89% −6.92% vs SPY
- Sep 2, 202610w ago Insider Cluster Neutral 4/10 Entry $10.64 to $10.49 Now $6.01 −43.52% ▼ −1.41% −0.26% vs SPY
- Aug 26, 202611w ago Insider Cluster Neutral 3/10 Entry $10.82 to $10.64 Now $6.01 −44.45% ▼ −1.66% −1.93% vs SPY
- Aug 3, 202615w ago 8-K Bullish 7/10 Entry $8.40 to $9.24 Now $6.01 −28.45% ▲ +10.00% +7.97% vs SPY
- Jun 17, 202621w ago Press Release Bullish 6/10 Entry $9.64 to $9.85 Now $6.01 −37.66% ▲ +2.18% +3.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers